PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
JD vs. CRSP
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between JD and CRSP is 0.30, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.0
Correlation: 0.3

Performance

JD vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in JD.com, Inc. (JD) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

50.00%100.00%150.00%200.00%250.00%300.00%NovemberDecember2025FebruaryMarchApril
49.58%
131.72%
JD
CRSP

Key characteristics

Sharpe Ratio

JD:

0.73

CRSP:

-0.96

Sortino Ratio

JD:

1.44

CRSP:

-1.52

Omega Ratio

JD:

1.17

CRSP:

0.84

Calmar Ratio

JD:

0.52

CRSP:

-0.59

Martin Ratio

JD:

2.13

CRSP:

-1.85

Ulcer Index

JD:

18.20%

CRSP:

26.79%

Daily Std Dev

JD:

53.36%

CRSP:

51.78%

Max Drawdown

JD:

-79.14%

CRSP:

-84.46%

Current Drawdown

JD:

-63.19%

CRSP:

-84.46%

Fundamentals

Market Cap

JD:

$60.40B

CRSP:

$2.80B

EPS

JD:

$3.70

CRSP:

-$4.34

PEG Ratio

JD:

1.27

CRSP:

-0.21

Total Revenue (TTM)

JD:

$898.77B

CRSP:

$36.12M

Gross Profit (TTM)

JD:

$107.27B

CRSP:

-$32.01M

EBITDA (TTM)

JD:

$40.00B

CRSP:

-$311.55M

Returns By Period

In the year-to-date period, JD achieves a 6.17% return, which is significantly higher than CRSP's -17.05% return.


JD

YTD

6.17%

1M

-15.88%

6M

-21.63%

1Y

40.93%

5Y*

-0.28%

10Y*

2.42%

CRSP

YTD

-17.05%

1M

-25.52%

6M

-28.04%

1Y

-49.82%

5Y*

-3.69%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

JD vs. CRSP — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

JD
The Risk-Adjusted Performance Rank of JD is 7676
Overall Rank
The Sharpe Ratio Rank of JD is 7979
Sharpe Ratio Rank
The Sortino Ratio Rank of JD is 7878
Sortino Ratio Rank
The Omega Ratio Rank of JD is 7474
Omega Ratio Rank
The Calmar Ratio Rank of JD is 7676
Calmar Ratio Rank
The Martin Ratio Rank of JD is 7676
Martin Ratio Rank

CRSP
The Risk-Adjusted Performance Rank of CRSP is 1010
Overall Rank
The Sharpe Ratio Rank of CRSP is 88
Sharpe Ratio Rank
The Sortino Ratio Rank of CRSP is 88
Sortino Ratio Rank
The Omega Ratio Rank of CRSP is 1212
Omega Ratio Rank
The Calmar Ratio Rank of CRSP is 1818
Calmar Ratio Rank
The Martin Ratio Rank of CRSP is 44
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

JD vs. CRSP - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for JD.com, Inc. (JD) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for JD, currently valued at 0.73, compared to the broader market-2.00-1.000.001.002.00
JD: 0.73
CRSP: -0.96
The chart of Sortino ratio for JD, currently valued at 1.44, compared to the broader market-6.00-4.00-2.000.002.004.00
JD: 1.44
CRSP: -1.52
The chart of Omega ratio for JD, currently valued at 1.17, compared to the broader market0.501.001.502.00
JD: 1.17
CRSP: 0.84
The chart of Calmar ratio for JD, currently valued at 0.52, compared to the broader market0.001.002.003.004.00
JD: 0.52
CRSP: -0.59
The chart of Martin ratio for JD, currently valued at 2.13, compared to the broader market-10.000.0010.0020.00
JD: 2.13
CRSP: -1.85

The current JD Sharpe Ratio is 0.73, which is higher than the CRSP Sharpe Ratio of -0.96. The chart below compares the historical Sharpe Ratios of JD and CRSP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.50-1.00-0.500.000.501.001.502.00NovemberDecember2025FebruaryMarchApril
0.73
-0.96
JD
CRSP

Dividends

JD vs. CRSP - Dividend Comparison

Neither JD nor CRSP has paid dividends to shareholders.


TTM202420232022
JD
JD.com, Inc.
0.00%2.13%2.08%2.21%
CRSP
CRISPR Therapeutics AG
0.00%0.00%0.00%0.00%

Drawdowns

JD vs. CRSP - Drawdown Comparison

The maximum JD drawdown since its inception was -79.14%, smaller than the maximum CRSP drawdown of -84.46%. Use the drawdown chart below to compare losses from any high point for JD and CRSP. For additional features, visit the drawdowns tool.


-90.00%-80.00%-70.00%-60.00%-50.00%NovemberDecember2025FebruaryMarchApril
-63.19%
-84.46%
JD
CRSP

Volatility

JD vs. CRSP - Volatility Comparison

The current volatility for JD.com, Inc. (JD) is 13.91%, while CRISPR Therapeutics AG (CRSP) has a volatility of 15.78%. This indicates that JD experiences smaller price fluctuations and is considered to be less risky than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%NovemberDecember2025FebruaryMarchApril
13.91%
15.78%
JD
CRSP

Financials

JD vs. CRSP - Financials Comparison

This section allows you to compare key financial metrics between JD.com, Inc. and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab